Related Experiment Video

Updated: Mar 3, 2026

Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice
08:15

Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice

Published on: September 17, 2015

20.1K

Candesartan in Heart Failure - Assessment of Reduction in Mortality and Morbidity (CHARM) Study Programme

K Swedberg1, M Pfeffer2, G B Granger3

  • 1a Department of Medicine, Sahlgrenska University Hospital/Ostra, Goteborg, Sweden.

Blood Pressure
|April 21, 2017
PubMed

Insights

Heart failure significantly impacts quality of life and survival. The CHARM program investigates candesartan cilexetil, an angiotensin II receptor blocker, to improve treatment outcomes for heart failure patients.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Heart failure is a prevalent condition causing significant mortality and morbidity.
  • Current treatments, including angiotensin-converting enzyme (ACE) inhibitors, have limitations, with high mortality rates persisting.
  • There is a critical need for improved therapeutic strategies in heart failure management.

Purpose of the Study:

  • To evaluate the clinical benefits of candesartan cilexetil, a long-acting angiotensin II type 1 (AT 1 ) receptor blocker.
  • To assess the efficacy of candesartan cilexetil in a broad spectrum of symptomatic heart failure patients.
  • To explore treatment effects based on left ventricular function and ACE inhibitor tolerance.

Main Methods:

  • The CHARM programme comprises three double-blind, randomized studies.
  • Patients were stratified according to left ventricular function.
  • Patient tolerance to ACE inhibitors was a key grouping factor.

Main Results:

  • Results are pending from the ongoing CHARM programme studies.
  • The studies aim to provide data on the efficacy of candesartan cilexetil in heart failure.

Conclusions:

  • The CHARM programme is expected to define the role of candesartan cilexetil in heart failure treatment.
  • Findings will inform clinical practice regarding the use of AT 1 receptor blockers.
  • Improved treatment strategies for heart failure may emerge from this research.

More Related Videos

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

4.3K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
6.9K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
431
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.1K
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.9K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.7K